Switch theme
Sign up to access all valuation multiples
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.
1988
382
LTM Revenue $277M
LTM EBITDA -$15.0M
$545M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Pharming has a last 12-month revenue of $277M and a last 12-month EBITDA of -$15.0M.
In the most recent fiscal year, Pharming achieved revenue of $267M and an EBITDA of $10.7M.
Pharming expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Pharming valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $224M | $267M | XXX | XXX | XXX |
| Gross Profit | $193M | $205M | XXX | XXX | XXX |
| Gross Margin | 86% | 77% | XXX | XXX | XXX |
| EBITDA | $36.5M | $10.7M | XXX | XXX | XXX |
| EBITDA Margin | 16% | 4% | XXX | XXX | XXX |
| Net Profit | $17.4M | $14.9M | XXX | XXX | XXX |
| Net Margin | 8% | 6% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of March 19, 2025, Pharming's stock price is EUR 1 (or $1).
Pharming has current market cap of EUR 552M (or $600M), and EV of EUR 501M (or $545M).
See Pharming trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $545M | $600M | XXX | XXX | XXX | XXX | $-0.02 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of March 19, 2025, Pharming has market cap of $600M and EV of $545M.
Pharming's trades at 1.8x LTM EV/Revenue multiple, and -33.5x LTM EBITDA.
Analysts estimate Pharming's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Pharming and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $545M | XXX | XXX | XXX |
| EV/Revenue | 2.0x | XXX | XXX | XXX |
| EV/EBITDA | 50.7x | XXX | XXX | XXX |
| P/E | -52.3x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -26.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpPharming's NTM/LTM revenue growth is 7%
Pharming's revenue per employee for the last fiscal year averaged $0.7M, while opex per employee averaged $0.7M for the same period.
Over next 12 months, Pharming's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Pharming's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Pharming and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 19% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 4% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -71% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 11% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.7M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.7M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 33% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 28% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 99% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Protalix | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Pharming acquired XXX companies to date.
Last acquisition by Pharming was XXXXXXXX, XXXXX XXXXX XXXXXX . Pharming acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Pharming founded? | Pharming was founded in 1988. |
| Where is Pharming headquartered? | Pharming is headquartered in Netherlands. |
| How many employees does Pharming have? | As of today, Pharming has 382 employees. |
| Who is the CEO of Pharming? | Pharming's CEO is Dr. Sijmen de Vries, M.D.. |
| Is Pharming publicy listed? | Yes, Pharming is a public company listed on AMS. |
| What is the stock symbol of Pharming? | Pharming trades under PHARM ticker. |
| When did Pharming go public? | Pharming went public in 1998. |
| Who are competitors of Pharming? | Similar companies to Pharming include e.g. Julphar, Galapagos, Vivoryon Therapeutics, Armata Pharmaceuticals. |
| What is the current market cap of Pharming? | Pharming's current market cap is $600M |
| What is the current revenue of Pharming? | Pharming's last 12-month revenue is $277M. |
| What is the current EBITDA of Pharming? | Pharming's last 12-month EBITDA is -$15.0M. |
| What is the current EV/Revenue multiple of Pharming? | Current revenue multiple of Pharming is 1.8x. |
| What is the current EV/EBITDA multiple of Pharming? | Current EBITDA multiple of Pharming is -33.5x. |
| What is the current revenue growth of Pharming? | Pharming revenue growth between 2023 and 2024 was 19%. |
| Is Pharming profitable? | Yes, Pharming is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
